Dr Reddy's Q4 Results 2025 Preview: Strong Growth Expected in Revenue and Profit, Say Top Brokerages

Dr Reddy's Laboratories, one of India's leading pharmaceutical companies, is anticipated to post a healthy rise in both revenue and net profit for the quarter ended March 2025 (Q4 FY25). Analysts attribute this projected growth to the integration of the Nicotinell acquisition, consistent performance in the US market, and positive momentum in the domestic business environment.

Dr Reddy's Laboratories Q4 FY25 Results Updates

The board of directors of the pharmaceutical company is scheduled to announce its financial results for the fourth quarter on Friday, May 9, 2025.

Dr Reddy's Lab Q4 2025 Preview: Profit Expectations

Market's top brokerage firms forecast suggest that Dr Reddy's Laboratories will report a net profit of approximately Rs 1,456.5 crore, reflecting a year-on-year (YoY) increase of about 18.6% compared to Rs 1,227.8 crore reported in Q4 FY24. On a quarter-on-quarter (QoQ) basis, this would represent a moderate profit growth of nearly 3%, indicating continued stability in the company's earnings.

Dr Reddy's Lab Q4 2025 Revenue Outlook: Boost from Acquisitions and US Market

The Indian pharmaceutical major is expected to record revenue of Rs 8,328.26 crore for the quarter, a 17.07% rise compared to Rs 7,113.8 crore in the same period last year. Sequentially, revenue is likely to remain steady, slightly lower than the Rs 8,358.6 crore recorded in Q3 FY25 for December 2024 quarter, signaling a period of consolidation post strong festive-season performance.

Dr Reddy's Lab Q4 2025 EBITDA Forecast

Brokerages also estimate the company's earnings before interest, tax, depreciation, and amortisation (EBITDA) to jump nearly 25% YoY to Rs 2,311.5 crore, up from Rs 1,849.8 crore in Q4 FY24.

Dr Reddy's Laboratories is poised for strong growth in Q4 FY25, supported by several strategic initiatives beyond its core operations. Key contributors include the Sanofi vaccine licensing deal, which expands its vaccine offerings in India, and a new joint venture with Nestle, likely aimed at boosting its presence in the wellness or pharmaceutical nutrition space.

The company is also benefiting from a 13% year-on-year growth in its domestic business In the U.S., Dr Reddy's maintains solid performance in its base generic drug portfolio, while its recent acquisition of Nicotinell is expected to generate operational synergies, cost efficiencies, and additional revenue, further strengthening its financial outlook.

Dr Reddy's Lab Q4 2025 Performance Overview by Top Brokerages:

According to analysts at Phillip Capital, the company's topline growth is expected to be driven by the successful integration of the Haleon OTC business, in particular the gRevlimid product, which continues to deliver impressive numbers. Dr Reddy's has emerged as a leading player in the gRevlimid space, generating around $160 million in sales during the quarter.

Phillip Capital also predicts that EBITDA margins will expand by 210 basis points YoY to 28.2%, driven largely by high-margin products like gRevlimid and consistent growth in India's prescription drug market. This would result in an EBITDA growth of 33% YoY.

Nirmal Bang Institutional Equities expects Dr Reddy's revenues to rise by 17.5% YoY, due to the acquisition of Nicotinell, a nicotine replacement therapy (NRT) brand.

Analysts at HDFC Securities project a 4% QoQ growth in the US business, largely sustained by gRevlimid sales, although they caution that rising competition could lead to price erosion in base products. For the Indian business, they forecast a 15% YoY increase, primarily driven by the integration of Sanofi's vaccine portfolio. The brokerage expects stable gross and EBITDA margins, indicating that recent acquisitions are being managed efficiently without adding cost pressures.